Premium
P1‐099: COMBINATION OF A GLUTAMINYL CYCLASE INHIBITOR (PQ912) AND A PYROGLUTAMATE‐Aβ SPECIFIC ANTIBODY (PBD‐M06) SHOWS ADDITIVE EFFECTS IN A MOUSE MODEL WITH ALZHEIMER'S DISEASE‐LIKE PATHOLOGY
Author(s) -
Hoffmann Torsten,
Farcher Martina,
Hutter-Paier Birgit,
Lemere Cynthia A.,
Schilling Stephan,
Lues Inge
Publication year - 2018
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2018.06.101
Subject(s) - antibody , immunohistochemistry , chemistry , genetically modified mouse , neurotoxicity , specific antibody , transgene , pharmacology , biochemistry , medicine , immunology , toxicity , gene
P1-099 COMBINATION OFA GLUTAMINYL CYCLASE INHIBITOR (PQ912) AND A PYROGLUTAMATE-Ab SPECIFIC ANTIBODY (PBD-M06) SHOWS ADDITIVE EFFECTS IN A MOUSE MODELWITH ALZHEIMER’S DISEASE-LIKE PATHOLOGY Torsten Hoffmann, Martina Farcher, Birgit Hutter-Paier, Cynthia A. Lemere, Stephan Schilling, Inge Lues, Probiodrug, Halle, Germany; QPS Austria, Grambach, Austria; QPS Austria GmbH, Grambach, Austria; Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA; Fraunhofer Institute for Cell Therapy and Immunology, Halle, Germany. Contact e-mail: stephan.schilling@izi. fraunhofer.de
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom